^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ZGGS15

    i
    Other names: ZGGS15, GS15, GS 15, ZGGS 15, GS-15, ZGGS-15
    Associations

    News

    Trials
    Company:
    Suzhou Zelgen
    Drug class:
    LAG-3 inhibitor, TIGIT inhibitor
    Related drugs:
    Associations

    News

    Trials
    14d
    Study of ZGGS15 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=22, Active, not recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Recruiting --> Active, not recruiting | N=36 --> 22 | Trial completion date: Aug 2024 --> Aug 2026 | Trial primary completion date: Aug 2024 --> Aug 2026
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • Metastases
    |
    ZGGS15
    8ms
    A novel anti-LAG-3/TIGIT bispecific antibody exhibits potent anti-tumor efficacy in mouse models as monotherapy or in combination with PD-1 antibody. (PubMed, Sci Rep)
    The tumor volume inhibition rate for ZGGS15 at 2 mg/kg was 69.70%, and for ZGGS15 at 5 mg/kg plus nivolumab at 1 mg/kg, it was 94.03% (p < 0.001). Our data reveal that ZGGS15 exhibits potent anti-tumor efficacy without eliciting ADCC or CDC or causing cytokine production, therefore having a safe profile.
    Preclinical • Journal • Combination therapy
    |
    TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • PVR (PVR Cell Adhesion Molecule)
    |
    Opdivo (nivolumab) • ZGGS15
    1year
    ZGGS15, a Novel IgG4 Bispecific Monoclonal Antibody Targeting Both LAG-3 and Tigit, Demonstrates Outstanding Anti-Tumor Activity and Can be Used As Monotherapy or in Combination with Anti-PD-1 Antibodies for Cancer Immunotherapy (ASH 2023)
    When combined with nivolumab, ZGGS15 can further enhance the T cell activation in a dose-dependent manner. Additionally, ZGGS15 does not elicit ADCC or CDC, therefore avoiding the cross-reaction of non-target binding. Finally, ZGGS15 does not induce cytokine production, mitigating any potential adverse effects of CRS.
    Combination therapy
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • IL6 (Interleukin 6) • LAG3 (Lymphocyte Activating 3) • TNFA (Tumor Necrosis Factor-Alpha) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • CD4 (CD4 Molecule) • IL2 (Interleukin 2) • IL10 (Interleukin 10) • PVR (PVR Cell Adhesion Molecule)
    |
    LAG3 expression
    |
    Opdivo (nivolumab) • ZGGS15
    over1year
    Study of ZGGS15 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=36, Not yet recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd
    New P1 trial • Metastases
    |
    ZGGS15